Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474840 | 0.92 | KMT2A (0.74) | KMT2AMEN1ALDH1A1MAPTPTGER1 | |
| SCHEMBL12055848 | 0.87 | KMT2A (0.47) | KMT2AMEN1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL4022887 | 0.80 | KMT2A (0.87) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4027607 | 0.80 | KMT2A (0.59) | KMT2AMEN1ALDH1A1MAPTPTGER1 | |
| SCHEMBL4023394 | 0.79 | KMT2A (0.79) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6375210 | 0.77 | KMT2A (0.81) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2959611 | 0.76 | KMT2A (0.64) | KMT2AMEN1ALDH1A1TP53MAPT | |
| SCHEMBL5899116 | 0.76 | CA1 (0.61) | KMT2AMEN1 | |
| SCHEMBL4028185 | 0.75 | KMT2A (0.73) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21579855 | 0.74 | POLB (0.65) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084464-B2 | Tetrahydroisoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084464-B2 | Tetrahydroisoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2231155-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192188-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192188-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009079637-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192188-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | HCRTR2, HCRTR1, OXTR | KMT2A 592/4885MEN1 860/4885ALDH1A1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.